Today, a Director at Intersect ENT (NASDAQ: XENT), Dana G. Mead, bought shares of XENT for $99.92K.
Following this transaction Dana G. Mead’s holding in the company was increased by 39.06% to a total of $356.1K. This is Mead’s first transaction since reporting a Buy transaction on TDOC back in March 2016
See today’s analyst top recommended stocks >>
Based on Intersect ENT’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $26.3 million and GAAP net loss of $4.16 million. In comparison, last year the company earned revenue of $23.99 million and had a GAAP net loss of $2.27 million. Currently, Intersect ENT has an average volume of 180.4K.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $34.67, reflecting a -24.3% downside. 11 different firms, including Merrill Lynch and Canaccord Genuity, currently also have a Buy rating on the stock. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy XENT with a $40 price target.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intersect ENT, Inc. is acommercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.
